Infection, Journal Year: 2025, Volume and Issue: unknown
Published: April 7, 2025
Language: Английский
Antibiotics, Journal Year: 2022, Volume and Issue: 11(6), P. 723 - 723
Published: May 27, 2022
Cefiderocol appears promising, as it can overcome most β-lactam resistance mechanisms (including β-lactamases, porin mutations, and efflux pumps). Resistance is uncommon according to large multinational cohorts, including against isolates resistant carbapenems, ceftazidime/avibactam, ceftolozane/tazobactam, colistin. However, alarming proportions of have been reported in some recent cohorts (up 50%). A systematic review was conducted PubMed Scopus from inception May 2022 resistance, prevalence heteroresistance, vivo emergence cefiderocol during treatment. variety mechanisms, typically acting concert, confer cefiderocol: β-lactamases (especially NDM, KPC AmpC variants conferring OXA-427, PER- SHV-type ESBLs), mutations affecting siderophore receptors, pumps, target (PBP-3) modifications. Coexpression multiple often combination with permeability defects, be the main mechanism resistance. Heteroresistance highly prevalent A. baumannii), but its clinical impact unclear, considering that low studies. Nevertheless, cases emerging are increasingly being reported. Continued surveillance cefiderocol’s activity important this agent introduced practice.
Language: Английский
Citations
155
Clinical Microbiology and Infection, Journal Year: 2023, Volume and Issue: 30(2), P. 178 - 188
Published: Sept. 4, 2023
Language: Английский
Citations
51
Journal of Clinical Pharmacy and Therapeutics, Journal Year: 2022, Volume and Issue: 47(11), P. 1875 - 1884
Published: Oct. 6, 2022
What is known and objective Acinetobacter baumannii one of the most important nosocomial pathogens with ability to cause infections such as meningitis, pneumonia, urinary tract, septicaemia wound infections. A wide range virulence factors are responsible for pathogenesis high mortality A. including outer membrane proteins, lipopolysaccharide, capsule, phospholipase, nutrient- acquisition systems, efflux pumps, protein secretion quarom sensing biofilm production. These contribute in pathogen survival stressful conditions antimicrobial resistance. Comment According World Health Organization (WHO), resistant ESKAPE group (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, baumannii, Pseudomonas aeruginosa Enterobacter spp.). In recent years, resistance a antibiotics has significantly increased emergence extensively drug (XDR) isolates challenging. Among therapeutic antibiotics, tigecycline last resort antibiotic become global concern. Several mechanisms involved resistance, which RND (Resistance-Nodulation-Division) family pumps overexpression. The development new strategies confront been very promising years. conclusion present review we highlight microbiological traits peruse novel options. focus on combination therapy, repurposing, bacteriophage peptides (AMPs), human monoclonal antibodies (Hu-mAbs), nanoparticles gene editing.
Language: Английский
Citations
43
Pathogens, Journal Year: 2023, Volume and Issue: 12(2), P. 286 - 286
Published: Feb. 9, 2023
Acinetobacter baumannii (AB) has evolved over the last decades as a major problem in carbapenem-resistant gram-negative nosocomial infections, associated with high mortality rates especially intensive care unit (ICU). Recent reports highlight increasing prevalence of resistance to colistin, resort therapeutic option for AB. We retrospectively evaluated characteristics, treatment regimens and outcomes twenty patients pan-drug resistant (PDR) AB primary bacteremia hospitalized ICU University General Hospital Patras, during two-year period (October 2020–September 2022). The 28-day reached 50%. Between survivors non-survivors, no differences were found regarding age, gender, Charlson comorbidity index (CCI). However, non-survivors had higher APACHE II scores septic shock COVID-19 infection. A significantly percentage survivor group received Fosfomycin part combination regimen. Inclusion fosfomycin regimen was better survival compared non-fosfomycin-containing regimens. In view PDR-AB infections ICUs, its lack effective options, observed benefit inclusion merits further validation larger prospective studies.
Language: Английский
Citations
25
Antibiotics, Journal Year: 2023, Volume and Issue: 12(6), P. 1012 - 1012
Published: June 5, 2023
The discovery of antibiotics has revolutionized medicine and changed medical practice, enabling successful fighting infection. However, quickly after the start antibiotic era, therapeutics for infectious diseases started having limitations due to development antimicrobial resistance. Since pipeline largely slowed down, with few new compounds being produced in last decades most them belonging already-existing classes, ways treat pathogens that are resistant is becoming an urgent need. To end, bacteriophages (phages), which already used some countries agriculture, aquaculture, food safety, wastewater plant treatments, could be also clinical practice against bacterial pathogens. Their one century ago was followed by studies showed optimistic results were limited, however, notable obstacles. rise during next left phage research inactive status. In decades, on phages have shown encouraging animals. Hence, further humans needed confirm their potential effective safe treatment cases where there or no other viable therapeutic options. This study reviews biology applications non-medical uses a narrative manner.
Language: Английский
Citations
23
Antibiotics, Journal Year: 2024, Volume and Issue: 13(5), P. 423 - 423
Published: May 6, 2024
Acinetobacter baumannii has emerged as a pressing challenge in clinical practice, mainly due to the development of resistance multiple antibiotics, including colistin, one last-resort treatments. This review highlights all possible mechanisms colistin and genetic basis contributing this resistance, such modifications lipopolysaccharide or lipid A structures, alterations outer membrane permeability via porins heteroresistance. In light escalating threat, also evaluates available treatment options. The new antibiotics (cefiderocol, sulbactam/durlobactam) although not everywhere, use various combinations synergistic drug (including two more following: polymyxin, ampicillin/sulbactam, carbapenems, fosfomycin, tigecycline/minocycline, rifamycin, aminoglycosides) are discussed context overcoming A. infections. Although most studied polymyxin-based combinations, non-polymyxin-based have been emerging promising However, data remain limited continued investigation is essential determine optimal therapeutic strategies against colistin-resistant baumannii.
Language: Английский
Citations
11
Future Microbiology, Journal Year: 2024, Volume and Issue: 19(7), P. 563 - 576
Published: March 1, 2024
Sulbactam–durlobactam is a pathogen-targeted β-lactam/β-lactamase inhibitor combination that has been approved by the US FDA for treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused susceptible isolates Acinetobacter baumannii–calcoaceticus complex (ABC) in patients 18 years age older. Sulbactam penicillin derivative with antibacterial activity against but prone to hydrolysis β-lactamases encoded contemporary isolates. Durlobactam diazabicyclooctane β-lactamase Ambler classes A, C D serine restores sulbactam both vitro vivo multidrug-resistant ABC. promising alternative therapy serious infections, which can have high rates mortality.
Language: Английский
Citations
10
Clinical Microbiology and Infection, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 1, 2025
Language: Английский
Citations
1
Microorganisms, Journal Year: 2022, Volume and Issue: 10(5), P. 849 - 849
Published: April 20, 2022
Background: Acinetobacter baumannii is a common cause of multi-drug (MDR)-resistant infections worldwide. The epidemiological and molecular characteristics MDR-A. in Jordan not known. Methods: A. isolates were collected from 2010 to 2020 three tertiary hospitals Jordan. Demographic clinical data, information, antibiotic susceptibility patterns, phenotypic, characterization carbapenem resistance genes performed. Results: A total 622 during the study period. Most males, aged 18−60 years, Jordanian, infected wounds, patients surgery or critical care units. Among whom was isolated, associated risk factors for MDR adults over 60, critically ill wounds (OR 4.14, 2.45, 10, 7, respectively, p < 0.0001). Incidence rates 2015 showed slight increase (3.75/1000 4.46/1000). Resistance patterns indicated high most cephalosporins, carbapenems, fluoroquinolones, moderate trimethoprim/sulfamethoxazole ampicillin/sulbactam, low aminoglycosides tetracyclines, while colistin tigecycline, have lowest rates. 76.8% 99.2% carbapenem-resistant. All positive OXA-51 gene (100%), 98.5% OXA-23 gene, 26.6% VIM KPC IMP almost detected (0% 0.8% respectively). Conclusions: This first large, multicentric, prolonged that provides insights into Attention at higher important early identification. Colistin tigecycline effective antimicrobials.
Language: Английский
Citations
32
Pharmaceutics, Journal Year: 2022, Volume and Issue: 14(6), P. 1266 - 1266
Published: June 14, 2022
Carbapenem-resistant Acinetobacter baumannii (CRAB) is becoming more widely recognized as a serious cause of nosocomial infections, and colistin has been reintroduced in recent years for the treatment CRAB infection. Combinations meropenem or imipenem have found to be effective against isolates, whereas clinical investigations not definitively demonstrated theoretical benefits combined therapy patients with infections. The objective this study was compare primary outcome (30-day survival rate) secondary outcomes (clinical response, microbiological response nephrotoxicity) between who received loading dose (LD) colistin−meropenem LD colistin−imipenem A retrospective cohort analysis performed at Chiang Mai University Hospital infection 2011 2017, 379 fulfilled requirements inclusion criteria. results showed that had lower 30-day rate (adjusted HR = 0.57, 95% CI: 0.37−0.90; p 0.015) (aHR 0.56, 0.35−0.90; 0.017) compared those colistin−meropenem. 0.52 times (aHR) than (95% 0.34−0.81; 0.004); however, there no significant difference nephrotoxicity 1.03, 0.67−1.57; 0.897) two combination regimens. In conclusion, when comparing meropenem, provides better treating CRAB. Thus, we suggest combinations should considered
Language: Английский
Citations
31